New treatment path for brain tumor patients

A University of Bristol report shows that fewer than 5% of eligible brain tumor patients receive genomic testing, highlighting unfair access. Led by the Tessa Jowell Brain Cancer Mission, the report stresses the importance of genomic tests to identify mutations and guide treatment. Regional disparities, long testing times, and other challenges are noted, with recommendations.